← All trials
NCT05567471
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 26, 2022
- Primary completion
- May 3, 2022
- Completion date
- Sep 28, 2022
- First posted
- Oct 5, 2022
- Last posted
- Oct 5, 2022
- Enrollment
- 875
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bharat Biotech International LimitedLead sponsor
- All India Institute of Medical SciencesOverall official - principal investigator
- All India Institute of Medical SciencesOverall official - principal investigator
- ESIC Medical College and Hospital FaridabadOverall official - principal investigator
- Jeevan Rekha Hospital, BelguamOverall official - principal investigator
- All India Institute of Medical SciencesOfficial
- All India Institute of Medical SciencesOfficial
- Jeevan Rekha Hospital, BelguamOfficial
- ESIC Medical College and Hospital FaridabadOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.